Choy Chi Tung, Siu Pui Ling Kella, Zhou Junwei, Wong Chi Ho, Lee Yuk Wai, Chan Ho Wang, Tsui Joseph Chi Ching, Lo Claudia Jun Yi, Loo Steven King Fan, Tsui Stephen Kwok Wing
Microbiome Research Centre, BioMed Laboratory Company Limited, Hong Kong.
Hong Kong Institute of Integrative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.
Microorganisms. 2023 Aug 28;11(9):2175. doi: 10.3390/microorganisms11092175.
Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a significant association with various type-2 inflammation-related comorbidities. Ongoing research suggests the crucial involvement of gut microbiome, especially in childhood onset AD, and hence, probiotics have emerged as a potential non-steroid-based therapeutics option to complement existing AD management plans. In order to delineate the impact of probiotics in the gut microbiome of pediatric AD patients from southern China, targeted 16S rRNA sequencing and thorough bioinformatic analysis were performed to analyze the gut microbiome profiles of 24 AD children after taking an orally administered novel synbiotics formula with triple prebiotics for 8 weeks. A notable improvement in Eczema Area and Severity Index (EASI) ( = 0.008) was observed after taking an 8-week course of probiotics, with no adverse effects observed. The relative abundances of key microbial drivers including and were significantly increased at week 8. We also found that the positive responsiveness towards an 8-week course of probiotics was associated with improvements in the gut microbiome profile with a higher relative abundance of probiotic species. Over-represented functional abundance pathways related to vitamin B synthesis and peptidoglycan recycling may imply the underlying mechanism. In summary, our study suggests how the gut microbial landscape shifts upon probiotic supplementation in AD children, and provides preliminary evidence to support targeted probiotic supplementation for the management of childhood AD.
特应性皮炎(AD)是一种常见的慢性炎症性皮肤病,与多种2型炎症相关的合并症密切相关。正在进行的研究表明肠道微生物群起着关键作用,尤其是在儿童期发病的AD中,因此,益生菌已成为一种潜在的非甾体类治疗选择,以补充现有的AD管理方案。为了阐明益生菌对中国南方儿科AD患者肠道微生物群的影响,我们进行了靶向16S rRNA测序和全面的生物信息学分析,以分析24名AD儿童口服含有三种益生元的新型合生元配方8周后的肠道微生物群谱。服用8周益生菌后,观察到湿疹面积和严重程度指数(EASI)有显著改善( = 0.008),且未观察到不良反应。在第8周时,包括 和 在内的关键微生物驱动因素的相对丰度显著增加。我们还发现,对8周益生菌疗程的积极反应与肠道微生物群谱的改善有关,益生菌种类的相对丰度更高。与维生素B合成和肽聚糖循环相关的功能丰度途径过度代表可能暗示了潜在机制。总之,我们的研究表明了AD儿童补充益生菌后肠道微生物景观如何变化,并提供了初步证据支持针对性补充益生菌用于儿童AD的管理。